Sunshine Biopharma Announces Canadian Subsidiary Nora Pharma Acquired Two Gastrointestinal Drugs; Launches Prucalopride For Chronic Constipation, Second Drug Launch Planned in 9 Months. Gastrointestinal Market Worth In Excess Of C$200M Per Year.

Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has acquired the rights to two gastrointestinal drugs and already launched one. The second is planned to be launched in the next 9 months.

The newly launched drug is Prucalopride, a generic version of Resotran®. In the United States, Prucalopride is sold under the brand name, Motegrity®. Prucalopride is indicated for the treatment of chronic idiopathic constipation in adult women for whom laxatives do not provide adequate relief. Prucalopride works by selectively stimulating the 5-HT4 receptors in the gastrointestinal tract. This action promotes cholinergic and non-adrenergic neurotransmission by enteric neurons, leading to increased peristaltic reflex, intestinal secretions, and overall gastrointestinal motility.

 

Both Prucalopride and the second drug Sunshine Biopharma is planning to launch by year end are in the chronic idiopathic constipation submarket of the total gastrointestinal market currently recording sales in excess of $200 million CAD per year (IQVIA data).

According to BioSpace, the chronic idiopathic constipation market is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.64% from 2024 to 2034. The demand is driven by the increasing prevalence of gastrointestinal disorders, particularly chronic idiopathic constipation, and the growing awareness of effective treatments.